openPR Logo
Press release

Overactive Bladder - Pipeline Review, H1 2017; New Report Launched

05-31-2017 11:38 AM CET | Health & Medicine

Press release from: DrugPipeline.net

DrugPipeline.net

DrugPipeline.net

Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2017, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 7, 5, 5, 2, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 114 pages “Overactive Bladder - Pipeline Review, H1 2017” report covers Introduction, Report Coverage, Overactive Bladder - Overview, Overactive Bladder - Therapeutics Development, Appendix, Methodology. The report covered companies are - Addex Therapeutics Ltd, Allergan Plc, Asahi Kasei Pharma Corp, Astellas Pharma Inc, Dompe Farmaceutici SpA, Dong-A ST Co., Ltd., FemmePharma Global Healthcare Inc, Hanmi Pharmaceuticals Co Ltd, Hydra Biosciences Inc

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/overactive-bladder-pipeline-review-h1-2017

Find all Diseases Reports at - http://www.drugpipeline.net/catalog/diseases

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Mr. Sudeep Chakravarty
Director - Operations
DrugPipeline.net
http://www.drugpipeline.net
Tel USA: +1-302-703-9904

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Overactive Bladder - Pipeline Review, H1 2017; New Report Launched here

News-ID: 556924 • Views:

More Releases from DrugPipeline.net

Global HLA Typing Transplant Market 2017-2021; New Report Launched
Global HLA Typing Transplant Market 2017-2021; New Report Launched
DrugPipeline.net has announced the addition of “Global HLA Typing Transplant Market 2017-2021” research report to their website www.DrugPipeline.net Human leukocyte antigen (HLA) is located in the chromosome 6, which is present in almost all nucleated cells. The HLA system includes a complex array of genes, which controls the immune response through recognition of self and non-self antigens, which can lead to graft rejection. HLA typing, also known as tissue typing, is
Global Surgical Instrument Tracking System Market Research Report 2017; New Report Launched
Global Surgical Instrument Tracking System Market Research Report 2017; New Repo …
DrugPipeline.net has announced the addition of “Global Surgical Instrument Tracking System Market Research Report 2017” research report to their website www.DrugPipeline.net Global Surgical Instrument Tracking System Market Research Report 2017, report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Surgical Instrument Tracking System in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India Global Surgical Instrument Tracking System market competition by
Global Orthopedic Navigation Systems Sales Market Report 2017; New Report Launched
Global Orthopedic Navigation Systems Sales Market Report 2017; New Report Launch …
Global Orthopedic Navigation Systems Sales Market Report 2017, report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Orthopedic Navigation Systems for these regions, from 2012 to 2022 (forecast), covering United States China Europe Japan Southeast Asia India Global Orthopedic Navigation Systems market competition by top manufacturers/players, with Orthopedic Navigation Systems sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players

All 4 Releases


More Releases for Overactive

Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Overactive Bladder Treatment Market? The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Overactive Bladder Treatment Market? The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from
Top Factor Driving Overactive Bladder Treatment Market Growth in 2025: Geriatric …
What industry-specific factors are fueling the growth of the overactive bladder treatment market? The anticipated growth of the overactive bladder treatment market is largely attributed to an increasing geriatric population. This term pertains to individuals who are 65 years old and above. The susceptibility of geriatric patients to urinary tract infections is higher due to multiple factors like reduced urine flow, overactive bladder, enlarged prostate or presence of kidney stones, thereby
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which
Overactive Bladder Market Report, History and Forecast 2022-2030
Overactive Bladder Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Overactive Bladder industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview
Overactive Bladder Treatment Market by Drug Type (Anticholinergics, Mirabegron, …
Market Analysis and Insights of Overactive Bladder Treatment Market During the forecasted period of 2023-2032, the market for treatments for overactive bladder will grow at a CAGR of about 4.00%. The main drivers of the overactive bladder treatment market's expansion are the rising prevalence of kidney-related disorders, increased emphasis on medical device research and development expertise and the adoption of cutting-edge IT healthcare technologies, an increasing geriatric population worldwide, and rising